| abstract |
- Compounds of formula 1 where: o A denotes a double bonded group selected from formula 2 and 3; and o X- denotes an anion with a single negative charge selected from among chloride, bromide, methylsulphate, 4-toluenesulpohonate and methanesulphonate; and o R1 and R2 which may be identical or different denote a group selected from among methyl, ethyl, n-propyl and isopropyl, which may optionally be substituted by hydroxyl or fluorine; and o R 3 R4, R5 and R6 which may be identical or different, denote hydrogen, methyl, ethyl, methoxy, ethyloxy, hydroxyl, fluorine, chlorine, bromine, CN, CF3 or NO2; o R7 denotes methyl, ethyl, methyloxy, ethyloxy, -CH2-F, -CH2-CH2-F, -O-CH2-F, -O-CH2-CH2OMe, -CH2-OEt, -CH2-CH2-OEt, -O-COMe, -O-COEt, -O-COCF3, -O-COCF3, fluorine, chlorine or bromine. - The use of compounds of formula 1 to treat asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract and menstrual disorders. - Pharmaceutical preparations of compounds of formula 1 may also be combined with other drugs such as betamimetics, antiallergic agents, PAF-antagonists, leukotriene-antagonists and steroids. - A process for the production of compounds of formula 1 is also disclosed. |